Sangamo Biosciences SVP Philip D. Gregory Unloads 15,000 Shares (SGMO)
Sangamo Biosciences (NASDAQ:SGMO) SVP Philip D. Gregory sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $12.54, for a total value of $188,100.00. Following the transaction, the senior vice president now directly owns 109,347 shares in the company, valued at approximately $1,371,211. The sale was disclosed in a document filed with the SEC, which is available at this link.
Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Sangamo Biosciences in a research note on Friday. They set an “overweight” rating and a $22.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $22.92.
Shares of Sangamo Biosciences (NASDAQ:SGMO) traded up 5.59% on Tuesday, hitting $13.60. 1,519,629 shares of the company’s stock traded hands. Sangamo Biosciences has a 1-year low of $8.93 and a 1-year high of $24.69. The stock has a 50-day moving average of $13.95 and a 200-day moving average of $16.14. The company’s market cap is $927.0 million.
Sangamo Biosciences (NASDAQ:SGMO) last announced its earnings results on Wednesday, July 23rd. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.14) by $0.04. The company had revenue of $10.38 million for the quarter, compared to the consensus estimate of $7.84 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. The company’s quarterly revenue was up 50.4% on a year-over-year basis. On average, analysts predict that Sangamo Biosciences will post $-0.26 earnings per share for the current fiscal year.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.